Batch manufacturing is the default. It does not have to be? Pharmaceutical manufacturing has operated on a batch model for decades: weigh raw materials, process them through discrete steps, hold intermediate products, test at defined intervals, and release the finished batch after quality review. This model works, but it introduces inefficiencies that continuous manufacturing eliminates. In continuous manufacturing, raw materials are fed into an integrated processing system that operates without interruption. Materials flow through synthesis, blending, granulation, tableting, and coating as a continuous stream rather than discrete batches. Process parameters are monitored and adjusted in real time. The system runs until the required quantity is produced or a quality deviation triggers a stop. The FDA has actively encouraged continuous manufacturing adoption since 2015, and several approved products (including Vertex’s Orkambi and Janssen’s Prezista) are manufactured using continuous processes. The regulatory pathway is established. The engineering challenge is maintaining process control in a system that never stops to be inspected. Practical comparison Dimension Batch manufacturing Continuous manufacturing Process flow Discrete steps with hold points Integrated continuous flow Quality testing End-of-batch testing In-line and at-line monitoring Scale-up Larger equipment for larger batches Longer run times, same equipment Changeover Between batches — cleaning, setup Less frequent but more complex Residence time Variable across batch Controlled and traceable Material waste Start-up and shutdown losses per batch Start-up/shutdown losses amortised over longer runs In our experience, the critical difference is the feedback loop. In batch manufacturing, quality deviations are typically detected after the batch is complete — during end-of-batch testing. If the batch fails, all material is potentially lost. In continuous manufacturing, deviations are detected in real time through process analytical technology (PAT), and only the affected material stream (measured in minutes of production) is diverted — not the entire batch. Why AI is structurally necessary Continuous manufacturing generates process data at a volume and velocity that manual monitoring cannot handle. A continuous oral solid dosage line produces temperature, humidity, particle size, blend uniformity, compression force, and tablet weight data continuously. Human operators cannot monitor all parameters simultaneously, detect subtle correlations between variables, or identify drift patterns that precede out-of-specification conditions. AI-based process control addresses this by learning the multivariate relationships between process parameters and product quality attributes. A machine learning model trained on historical process data can predict when a combination of parameter trends will produce out-of-specification product — before the product is actually out of specification. This enables proactive adjustment rather than reactive diversion. Real-time release testing (RTRT) — where product is released based on process data rather than end-product testing — is the regulatory framework that makes this practically valuable. FDA and EMA support RTRT for continuous manufacturing when the process monitoring system can demonstrate that process controls are equivalent to or better than traditional end-product testing. These process control applications are among the proven AI use cases in pharmaceutical manufacturing that deliver measurable quality and efficiency improvements with established regulatory pathways. The system lifecycle for pharmaceutical AI Pharmaceutical software follows a defined lifecycle: requirements, design, implementation, testing, deployment, operation, and retirement. AI systems add complexity because the “implementation” phase includes model training, which is inherently iterative and data-dependent. The lifecycle must accommodate model retraining, performance monitoring, and drift detection as ongoing operational activities — not as one-time validation events. Regulatory expectations require that each lifecycle phase produces documented evidence. For AI systems, this means documenting training data provenance, model selection rationale, validation test protocols and results, deployment criteria, monitoring procedures, and retirement criteria. The documentation should be sufficient for a qualified person to understand what the system does, how it was validated, and how its performance is monitored. In practice, we structure the AI system lifecycle into two phases: the initial deployment (which follows a traditional V-model validation approach adapted for ML) and the operational phase (which follows a continuous validation approach with defined performance thresholds, automated drift detection, and change control procedures for model updates). This dual-phase approach satisfies both the initial validation requirement and the ongoing assurance requirement that regulators expect for non-deterministic systems. The validation challenge Continuous manufacturing AI systems face a specific validation challenge: the system must be validated for a process that operates continuously, with model inputs that change over time. Traditional IQ/OQ/PQ validation — designed for systems that can be tested in a controlled state — must be adapted for systems that are always running. Our approach in these deployments is to validate the model’s performance envelope (the range of conditions under which it reliably predicts quality outcomes) and implement continuous monitoring to confirm that the process remains within that envelope. When conditions move outside the validated envelope — due to raw material variability, equipment wear, or environmental changes — the system flags the deviation and triggers human review.
